RxDoctor Payments Data

Jonas Gricius, MD

Urology · Bangor, MENPI 1659534782

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Procept Biorobotics Corporation at 51.5% of the total. Reporting peaked in 2023 at $703 and has fallen 74.4% since, to $180 in 2025. That places this record below the midpoint for urology clinicians in ME, where the typical reported total is $1,024.

$1,052in general payments, 2019–2025

Across 13 payments — averaging $80.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$541
  • Conmed Corporation$122
  • Janssen Scientific Affairs, LLC$108
  • Pfizer$84
  • Astellas Pharma US Inc$52
  • Urogen Pharma, Inc.$51
  • plus $93 from 3 others

What the payments were for

  • Travel & lodging$54151%
  • Food & beverage$32631%
  • Education$18518%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,052 in reported general payments places this provider in the 50th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$85,267
Medicare patients
319
Services billed
811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$43,171
Silodosin96$7,936
Tamsulosin Hcl215$3,522
Solifenacin Succinate16$991
Oxybutynin Chloride19$843
Finasteride49$786
Alfuzosin Hcl ErAlfuzosin Hcl44$632
Dutasteride31$520
Cefdinir25$517
Doxazosin Mesylate18$344
Bicalutamide22$317
Ketorolac Tromethamine12$238
Terazosin Hcl18$227
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$196
Levofloxacin61$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$52$43,17159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 59 urology providers in Maine.

Other urology in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →